Skip to main
RXST

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 0%
Hold 67%
Sell 22%
Strong Sell 0%

Bulls say

RxSight Inc. has demonstrated a robust growth trajectory with a year-over-year revenue increase that beat consensus expectations, supported by strategic initiatives aimed at enhancing Light Adjustable Lens (LAL) volumes. The company is well-positioned to achieve double-digit growth, fueled by an expanding installed base of LDDs and increased utilization rates. Furthermore, management's guidance for improved gross margins, raised to 76-77%, indicates a positive outlook for profitability alongside a commitment to controlled operating expenses.

Bears say

RxSight Inc. has experienced a decline in key financial metrics, with a 14% year-over-year decrease in revenue to $30.3 million and a significant drop in the monthly utilization of light adjustable lenses (LALs), falling to 8.0 per laser delivery device (LDD) from 10.1 a year earlier. Furthermore, LDD placements in the second quarter of 2025 were substantially lower than expected, down 68% year-over-year and 38% quarter-over-quarter, leading to a projected total of only 150 placements for the year. The company faces multiple risks, including limited adoption due to the requirement for capital equipment, disappointing commercial execution, increasing competition in the intraocular lens market, and the potential necessity for dilutive financing.

RxSight (RXST) has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 22% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Hold based on their latest research and market trends.

According to 9 analysts, RxSight (RXST) has a Hold consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.